PofoliaShared via Pofolia

JCO Precision Oncology· 2017Q1

Landscape of Microsatellite Instability Across 39 Cancer Types

Russell Bonneville, Melanie A. Krook, Esko A. Kautto, Jharna Miya et al.

Short summary

Microsatellite instability (MSI) was identified in 3.8% of 11,139 tumors across 27 cancer types, including adrenocortical carcinoma, cervical cancer, and mesothelioma, where it was previously under-recognized.

AI-generated from the title and abstract; the full text is not read.

Key points

  • MSI was detected in 3.8% of 11,139 tumors across 39 cancer types.
  • MSI was identified in 27 tumor types, with notable prevalence in adrenocortical carcinoma, cervical cancer, and mesothelioma.
  • MSI-high adrenocortical carcinoma and cervical cancer tumors exhibited a higher average mutational burden compared to their microsatellite-stable counterparts.
  • The findings suggest an expanded role for clinical MSI testing beyond current recommendations for colorectal and endometrial cancers.

AI-generated from the title and abstract; the full text is not read.

Abstract

PURPOSE: Microsatellite instability (MSI) is a pattern of hypermutation that occurs at genomic microsatellites and is caused by defects in the mismatch repair system. Mismatch repair deficiency that leads to MSI has been well described in several types of human cancer, most frequently in colorectal, endometrial, and gastric adenocarcinomas. MSI is known to be both predictive and prognostic, especially in colorectal cancer; however, current clinical guidelines only recommend MSI testing for colorectal and endometrial cancers. Therefore, less is known about the prevalence and extent of MSI among other types of cancer. METHODS: Using our recently published MSI-calling software, MANTIS, we analyzed whole-exome data from 11,139 tumor-normal pairs from The Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments projects and external data sources across 39 cancer types. Within a subset of these cancer types, we assessed mutation burden, mutational signatures, and somatic variants associated with MSI. RESULTS: We identified MSI in 3.8% of all cancers assessed-present in 27 of tumor types-most notably adrenocortical carcinoma (ACC), cervical cancer (CESC), and mesothelioma, in which MSI has not yet been well described. In addition, MSI-high ACC and CESC tumors were observed to have a higher average mutational burden than microsatellite-stable ACC and CESC tumors. CONCLUSION: We provide evidence of as-yet-unappreciated MSI in several types of cancer. These findings support an expanded role for clinical MSI testing across multiple cancer types as patients with MSI-positive tumors are predicted to benefit from novel immunotherapies in clinical trials.

The authors' abstract, as published at the source. JCO Precision Oncology, 2017 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine